Friday 5-16-2014 Gilead Sciences (GILD) $GILD open
Post# of 162
Posted On: 05/17/2014 12:56:00 PM
Friday 5-16-2014 Gilead Sciences (GILD) $GILD opened at 80.30 hitting the high price of 80.84 and a day low of 79.22 with a total volume of 10,525,700. GILD had a previous close of 80.10 and has been seeing an average volume of 16,749,580.
Overall Average: 72% Buy
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - 2 hrs 4 mins ago
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S.... (full story)
Can CVS Overcome the Drug Poised to "Break the Country?"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 16, 5:30PM CDT
Consider the following quotes: "What they have done with this particular drug will break the country." "We expect the impact to be minimal for this year." These two quotes, the first from Express Scripts ' chief medical officer Steven... (full story)
Final Glance: Biotechnology companies
AP - Fri May 16, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress. (full story)
Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin). (full story)
Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study. (full story)
Midday Glance: Biotechnology companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)
XenoPort - Reckitt Benckiser Pharma Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 10:50AM CDT
XenoPort, Inc. (XNPT) announced a deal with Reckitt Benckiser Pharmaceuticals for the development and commercialization of XenoPort's arbaclofen placarbil. (full story)
Early Glance: Biotechnology companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 16, 8:46AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, with shares rising over 19% on the day. (full story)
Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,... (full story)
Clovis Oncology, Inc. (CLVS) in Focus: Stock Surges 16 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 16, 7:44AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session as the company saw its shares surge 16% on the day. (full story)
Pipeline Breakdown: Merck & Co. Inc.
Brian Orelli, The Motley Fool - Motley Fool - Thu May 15, 5:30PM CDT
Merck recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors... (full story)
Incyte to Collaborate with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:30PM CDT
Incyte Corporation (INCY) inked a deal with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). (full story)
Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study. (full story)
Novartis Settles Gleevec Patent Litigation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:40AM CDT
Novartis (NVS) has settled its litigation with the subsidiary of Sun Pharmaceutical Industries Ltd. in the U.S. (full story)
Progenics' Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:10AM CDT
Progenics Pharmaceuticals, Inc.'s (PGNX) loss narrows in the first quarter of 2014. (full story)
Overall Average: 72% Buy
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - 2 hrs 4 mins ago
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S.... (full story)
Can CVS Overcome the Drug Poised to "Break the Country?"
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri May 16, 5:30PM CDT
Consider the following quotes: "What they have done with this particular drug will break the country." "We expect the impact to be minimal for this year." These two quotes, the first from Express Scripts ' chief medical officer Steven... (full story)
Final Glance: Biotechnology companies
AP - Fri May 16, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress. (full story)
Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin). (full story)
Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study. (full story)
Midday Glance: Biotechnology companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)
XenoPort - Reckitt Benckiser Pharma Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 10:50AM CDT
XenoPort, Inc. (XNPT) announced a deal with Reckitt Benckiser Pharmaceuticals for the development and commercialization of XenoPort's arbaclofen placarbil. (full story)
Early Glance: Biotechnology companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 16, 8:46AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, with shares rising over 19% on the day. (full story)
Drug-Pricing Rhetoric: Should Investors be Worried?
Brian Orelli, The Motley Fool - Motley Fool - Fri May 16, 8:30AM CDT
The drug-pricing story just won't go away. Bloomberg had a long article about the price of drugs claiming that there might be a drug that cost $1 million annually shortly. The pricing issue has previously been limited to orphan drug indications,... (full story)
Clovis Oncology, Inc. (CLVS) in Focus: Stock Surges 16 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 16, 7:44AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session as the company saw its shares surge 16% on the day. (full story)
Pipeline Breakdown: Merck & Co. Inc.
Brian Orelli, The Motley Fool - Motley Fool - Thu May 15, 5:30PM CDT
Merck recently held its analyst day, updating analysts and investors listening in on its pipeline. While there weren't any major announcements -- no high-profile clinical trial results were announced -- there were a few tidbits that investors... (full story)
Incyte to Collaborate with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:30PM CDT
Incyte Corporation (INCY) inked a deal with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). (full story)
Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study. (full story)
Novartis Settles Gleevec Patent Litigation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:40AM CDT
Novartis (NVS) has settled its litigation with the subsidiary of Sun Pharmaceutical Industries Ltd. in the U.S. (full story)
Progenics' Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:10AM CDT
Progenics Pharmaceuticals, Inc.'s (PGNX) loss narrows in the first quarter of 2014. (full story)
(0)
(0)Gilead Sciences Inc. (GILD) Stock Research Links
Scroll down for more posts ▼